Responses of Coxsackievirus B4-Specific T-Cell Lines to 2C Protein—Characterization of Epitopes with Special Reference to the GAD65 Homology Region  by Marttila, Jane et al.
1
C
S
3
Virology 284, 131–141 (2001)
doi:10.1006/viro.2001.0917, available online at http://www.idealibrary.com onResponses of Coxsackievirus B4-Specific T-Cell Lines to 2C Protein—Characterization of
Epitopes with Special Reference to the GAD65 Homology Region
Jane Marttila,*,†,1 Sirpa Juhela,*,† Outi Vaarala,‡ Heikki Hyo¨ty,*,§ Merja Roivainen,‡ Ari Hinkkanen,¶
Pekka Vilja,§ Olli Simell,*,\ and Jorma Ilonen*,†
*JDFI Centre for Diabetes Prevention in Finland, †Department of Virology, and \Department of Pediatrics, University of Turku, FIN-20520 Turku,
Finland; ‡National Public Health Institute, Helsinki, Finland; §Department of Virology, University of Tampere Medical School and Tampere
University Hospital, Tampere, Finland; and ¶Department of Biochemistry and Pharmacy, Åbo Akademi University, Turku, Finland
Received November 28, 2000; returned to author for revision February 7, 2001; accepted March 9, 2001
Coxsackie B viruses (CBV) have been indicated as environmental triggers initiating autoimmune destruction of insulin-
producing pancreatic b-cells, and molecular mimicry might be the mechanism. A prime candidate for inducing cross-reactive
immune responses is a homology sequence, PEVKEK, found both in CBV4 2C protein and in GAD65. To characterize the
CBV4-specific T-cell epitopes, overlapping peptides covering the 2C protein were synthesized and CBV4-specific T-cell lines
were established from healthy and diabetic subjects. The T-cell epitopes were dependent on the HLA-DR genotype of the
T-cell donor, but no difference between diabetic and healthy subjects could be detected. Peptide p4, which included the
PEVKEK sequence, contained an HLA-DR1-restricted T-cell epitope. Three randomly selected CBV4-specific T-cell lines,
which responded to peptide p4, failed to recognize GAD65 protein or GAD65 peptides containing the PEVKEK sequence. We
conclude that the CBV4 2C protein is strongly immunogenic for T-cells and PEVKEK is included in a T-cell epitope. However,
presentation of this epitope in the context of neutral HLA-DR1 allele does not support its role in pathogenesis of type 1
diabetes. © 2001 Academic Press
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VINTRODUCTION
Enteroviruses are common human pathogens which
have a considerable clinical significance even after erad-
ication of polioviruses (Melnick, 1995). Classification of
enteroviruses has been traditionally based on their
pathogenicity in experimental animals and distinction
between serotypes on reactivity of neutralizing antibod-
ies, but recently classification based on genomic studies
has also been suggested (Hyypia¨ et al., 1997). Most
infections are subclinical or accompanied by mild com-
mon cold-type symptoms but several distinct complica-
tions also occur like meningitis, myocarditis, and gener-
alized serious infection in newborns. The specific clinical
manifestations, which also include rash; hand, foot, and
mouth disease; herpangina; and pleurodynia, are more
or less tightly associated with specific enterovirus sero-
types (Melnick, 1995). Increasing evidence also impli-
cates that enteroviruses are among environmental trig-
gers in the pathogenesis of autoimmune diabetes (An-
dreoletti et al., 1997; Banatvala et al., 1985; Frisk et al.,
985; Hiltunen et al., 1997; Hyo¨ty et al., 1995; Jones and
rosby, 1996; Juhela et al., 1999, 2000; Nairn et al., 1999;
zopa et al., 1993).
Immunity against enterovirus infections is created by1 To whom reprint requests should be addressed. Fax: 1358 2 251
303. E-mail: jane.marttila@utu.fi.
131he presence of neutralizing antibodies, which by defini-
ion are serotype specific. Cross-reactive antibodies are,
owever, also induced during infections and these anti-
odies are utilized in serological laboratory diagnosis
Melnick, 1995). The significance of cell-mediated immu-
ity has not been extensively analyzed but it may be
nvolved in the development of disease-associated com-
lications (Beck et al., 1990; Henke et al., 1995). Both
ross-reactive and serotype-specific T-cell epitopes have
een described in structural proteins but cellular re-
ponses to nonstructural proteins have not been system-
cally studied (Beck and Tracy, 1990; Cello et al., 1996;
raham et al., 1993). Many of these proteins are highly
onserved among different enteroviruses, which indi-
ates that cell-mediated immunity directed against them
ould be largely cross-reactive (Jenkins et al., 1987;
reugdenhil et al., 1998).
The 2C protein is one of the nonstructural proteins
with largely unknown function. It is apparently required in
the initiation and elongation phases in RNA synthesis
(Cho et al., 1994). A sequence of six identical amino
acids (aa) is shared by the 2C protein of coxsackievirus
B4 (CBV4) and the 65-kDa glutamic acid decarboxylase
(GAD65) molecule (Kaufman et al., 1992), which is one of
the major autoantigens in type 1 diabetes (Atkinson et
al., 1990; Baekkeskov et al., 1987). Studies analyzing the
possible role of molecular mimicry in type 1 diabetes
have been largely focused on this sequence. Antibody
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132 MARTTILA ET AL.cross-reactivity between GAD65 autoantigen and 2C pro-
tein has been shown under certain experimental condi-
tions but its pathogenetic significance has not been
confirmed (Hou et al., 1994; Lo¨nnrot et al., 1996). Studies
f NOD mice have also demonstrated that T-cells cross-
eact with these two polypeptides (Tian et al., 1994), and
ynthetic peptides covering the homology region have
een reported to stimulate human peripheral blood lym-
hocytes more often in patients with type 1 diabetes than
n healthy controls (Atkinson et al., 1994).
Recent evidence shows that T-cells may cross-react
ith several synthetic peptides. The identity or similarity
f amino acids at the key positions binding to the MHC
olecule and T-cell receptor is important, but exact
mino acid homology is not compulsory (Hemmer et al.,
998; Nanda et al., 1995; Wucherpfennig and Strominger,
995). Although microbial polypeptides as a rule contain
everal binding motifs that are able to bind MHC mole-
ules and stimulate T-cells, T-cell responses are formed
o only few epitopes in each protein during natural infec-
ions, a phenomenon called immunodominance. The ex-
ct epitope that leads to T-cell activation is defined by
he HLA genotype of the responder. It is not known
hether the homology region in CBV4 2C and GAD65
olecule is part of the T-cell epitope recognized by cells
ctivated during enterovirus infections. To answer this
uestion we established CBV4-specific T-cell lines from
oth healthy volunteers and diabetic patients. T-cell
pitopes of CBV4 2C protein were analyzed using 20-
mino-acid-long overlapping peptides in lymphocyte pro-
iferation test and by measuring interferon-g production
by the T-cells as a sign of T-cell activation.
RESULTS
Characterization of T-helper cell epitopes on
coxsackievirus B4 2C protein by proliferation test
CBV4-specific T-cell lines were established from 22
donors. Nineteen of the T-cell lines recognized 2C pep-
tides, whereas 3 T-cell lines failed to respond to the 2C
peptides or to the purified 2C protein. CBV4-specific
T-cell lines from 11 of the 13 healthy controls and from 8
of the 9 patients with type 1 diabetes responded to the
2C peptides. The epitopes detected by these lines were
mapped using 33 different 20-aa-long peptides overlap-
ping with each other by 10 aa and covering the whole
sequence of the CBV4 2C protein. Peptides recognized
by the T-cell lines were widely distributed along the
sequence and differed markedly from one subject to the
next. Peptides p9 and p22 stimulated T-cells most often,
as they were both recognized by 7 T-cell lines. Peptides
p2, p19, and p25 were all recognized by 6 T-cell lines
(Table 1). Individual CBV4-specific T-cell lines responded
to up to 13 different peptide epitopes with a stimulation
index (SI) .3. The number of the peptides recognized by
each T-cell line depended on the HLA-DR type of the
p
fdonor. T-cell lines sharing the same HLA-DR type were
as a rule stimulated by the same peptides. Interestingly,
T-cell lines established from donors with both HLA-DR1
and HLA-DR3 responded to a large number of epitopes.
Peptides p2, p4, p9, p22, and p25 were most often rec-
ognized (Fig. 1). T-cell lines from donors with HLA-DR4
responded to only few peptide epitopes (Fig. 2), and 3 of
those lines (of 8) responded to only the CBV4 antigen
and did not recognize any of the synthetic peptides. P17
was the peptide most often recognized by the HLA-DR4-
positive T-cell lines, as 2 lines responded strongly to this
peptide (SI . 3) and 2 others showed a marginal (2 ,
SI , 3) response.
Recognition of peptide epitopes by cytokine
production
T-cell proliferation responses and interferon-g produc-
tion by the CBV4-specific T-cell lines after exposure to
the 2C peptides correlated quite well (Fig. 3). Strong
positive responses were usually detected with both pro-
liferation assay and interferon-g production. However,
ome T-cell lines produced interferon-g in response to
eptides which did not induce proliferation. These pep-
ides were usually the same peptides which induced
TABLE 1
Positive Responses (SI . 3) of CBV4-Specific Human T-Helper Cell
Lines to 20-aa-Long Peptides Covering CBV4 2C Protein
Peptide HLA-DR types of the donors of the responding T-cell lines
p1 DR2
p2 DR1; DR1,3; DR3,6; DR1,3; DR1,3; DR1,3
p4 DR1,3; DR1,3; DR1,3
p7 DR1,3; DR3; DR1,3
p9 DR1; DR1,3; DR3,6; DR1,3; DR1,3; DR3; DR1,3
p10 DR1,3; DR1,3; DR1,3; DR3,9
p11 DR6,9; DR2; DR1,3; DR3,5; DR1,3
p12 DR6,9; DR2; DR1,3
p13 DR1,3
p17 DR4,6; DR1,4
p18 DR4,6; DR3; DR1,3
p19 DR2,4; DR1,3; DR2,3; DR4,9; DR1,3; DR1,3
p21 DR3; DR1,3
p22 DR2; DR3; DR1,3; DR1,3; DR4; DR4,9; DR1,3
p23 DR4,9
p24 DR6,9; DR3; DR1,3; DR1,3
p25 DR6,9; DR3; DR1,3; DR1,3; DR1,3; DR3,9
p26 DR4,9; DR1,3
p30 DR1,3; DR1,3
p31 DR4,9
p32 DR3; DR1,3
Note. T-cell lines derived from children with type 1 diabetes are
written using bold letters.ositive proliferation response with other T-cell lines
rom donors having similar HLA-DR type.
133RESPONSES OF CBV4-SPECIFIC T-CELL LINES TO 2C PROTEINFIG. 1. Responses of three coxsackievirus B4 (CBV4)-specific T-cell lines from different donors sharing HLA-DR1,3 genotype to 33 overlapping
20-aa-long peptides (p1–p33) covering the full sequence of the CBV4 2C protein. T-cell lines B and C were established from donors with type 1
diabetes. med, culture medium without the antigens.
134 MARTTILA ET AL.FIG. 2. Responses of three coxsackievirus B4 (CBV4)-specific T-cell lines from different donors with type 1 diabetes sharing HLA-DR4 allele to 33
overlapping 20-aa-long peptides (p1–p33) covering the full sequence of the CBV4 2C protein. med, culture medium without the antigens.
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136 MARTTILA ET AL.Responses to the peptide epitopes by T-cell lines
from patients with type 1 diabetes
As the number of T-cell lines studied was low (Table 1)
possible differences between the peptides recognized
by the diabetic subjects and the healthy controls remain
preliminary. None of the peptides was recognized by
every T-cell line established from the diabetic subjects.
Peptide p17 was recognized solely by T-cells from dia-
betic donors with HLA-DR4 molecule but only one of five
T-cell lines from subjects with HLA-DR4 was derived
from a healthy control. Other than this, only T-cell lines
which were established from diabetic individuals
showed strong (SI . 3) responses to peptides p13, p18,
23, p26, p31, and p32, but T-cell lines from healthy
ontrols responded weakly (2 , SI , 3) to these pep-
tides. T-cell lines from type 1 diabetes patients and
healthy controls produced similar amounts of inter-
feron-g.
-cell proliferation and interferon-g responses to the
AD65 homology region
Peptide p4 (WLKVKILPEVKEKHEFLSRL) of the 2C pro-
ein included the sequence homology area (PEVKEK)
ith the human GAD65 protein. Three different CBV4-
pecific T-cell lines derived from donors positive for both
LA-DR1 and HLA-DR3 molecules responded strongly
SI . 3) to the peptide p4 (Table 1). One of the donors
ad type 1 diabetes, whereas the two others were
ealthy controls. Three other T-cell lines, one estab-
ished from a type 1 diabetes patient with HLA-DR1,3
enotype and two from healthy controls with HLA-DR1
nd HLA-DR3,6 showed marginal responses (2 , SI , 3)
o p4.
Presentation of peptide p4 by autologous PBMCs to
-cells was inhibited mainly by anti-HLA-DR mAb and not
y anti-HLA-DQ mAb or anti-HLA-ABC mAb (data not
T
Response of Coxsackievirus B4 (CBV4)-Specific T-Cell Line from a
edium without Antigens (Medium), or p4 (WLKVKILPEVKEKHEFLS
ntigens
Antigen
HLA-
DR1,3 DR2,5
CBV4 4238 965
(23.0) (0.6)
Medium 184 1569
(1.0) (1.0)
p4 4689 997
(25.5) (0.6)
Note. The responses are expressed in counts per minute and in pahown). HLA-DR restriction of p4 presentation was stud-
ed using antigen-presenting cells that expressed eitherR1 or DR3 molecule in common with T-cell donors with
LA-DR1,3 genotype. Autologous cells and cells without
ny common DR alleles served as positive and negative
ontrols, respectively. When peptide p4 was presented
y autologous cells or by cells positive for DR1 molecule
he T-cell lines showed strong proliferative responses. In
ur series of experiments, APC sharing only the HLA-
R3 molecule with T-cell line donors were never able to
resent peptide p4 (Table 2).
We also synthesized a truncated 12-aa-long peptide,
ILPEVKEKHEF, which induced proliferation response
nd interferon-g production similar to that of the original
p4 peptide, demonstrating that PEVKEK sequence was
part of the T-cell epitope (Fig. 4). The importance of this
core sequence was further shown by the 20-aa peptide
synthesized according to the known sequence of CBV3
2C protein, WLKVKILPEVREKHEFLNRL, which differs
only for a lysine (p4) to arginine substitution. This peptide
failed to stimulate the T-cell line responding to the re-
spective CBV4 peptide p4, WLKVKILPEVKEKHEFLNRL
(Fig. 4).
Responses to GAD65 and to GAD65 peptides
containing the 2C homology area
The responses to purified human GAD65 were studied
with four CBV4-specific T-cell lines derived from two
patients with type 1 diabetes and from two healthy con-
trols. These T-cell lines showed no responses to GAD65
although three of these lines had responded to p4 pep-
tide. These CBV4-specific T-cell lines neither showed
any responses to the GAD65 peptides containing the 2C
homology region (IARFKMFPEVKEKGMAALPR, KMFPE-
VKEKGMAALPRLIAF, NMYAMMIARFKMFPEVKEKG)
(Fig. 4).
DISCUSSION
R1,3 Heterozygous Lymphocyte Donor When CBV4 Antigen, Control
ptide Was Presented by Cells from Donors with Different HLA-DR
e of antigen-presenting cells
DR1,7 DR2,3 DR3
2483 1556 1297
(14.3) (1.9) (3.3)
174 822 395
(1.0) (1.0) (1.0)
1452 1536 292
(8.3) (1.9) (0.7)
es as stimulation indexes, as defined under Materials and Methods.ABLE 2
HLA-D
RL) Pe
DR typ
DR1
3212
(11.8)
272
(1.0)
2814
(10.3)Most studies of immunogenic sites in enterovirus pro-
teins have previously focused on capsid proteins, and
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137RESPONSES OF CBV4-SPECIFIC T-CELL LINES TO 2C PROTEINlittle information is available on immune responses to the
nonstructural proteins. Beck and co-workers demon-
strated in a mouse model that the nonstructural 2C
protein contains immunogenic epitopes that are recog-
nized by the T-cells (Beck et al., 1992). Recently we and
the others showed that 2C protein is a target of T-cell
immunity also in humans (Juhela et al., 2000; Varela-
alvino et al., 2000). In the present work we have char-
acterized human T-helper cell responses to the epitopes
in the nonstructural 2C protein of CBV4. CBV4-specific
T-cell lines were established by stimulating PBMC with a
lysate of cells infected by coxsackievirus B4 so that the
antigen mixture used contained all structural and non-
structural viral proteins. Nineteen of the 22 (86%) CBV4-
specific lines responded strongly to the 2C protein, indi-
cating its importance as a target of T-cell immunity. The
nonstructural proteins are formed from a highly con-
served polyprotein so that the published 2C sequences
of various coxsackievirus B serotypes differ only by 7 to
9 amino acids (of 329 amino acids). Most T-cell epitopes
in 2C protein are thus common to several enteroviruses
and repeated infections caused by various enterovirus
serotypes may thus enhance responses to them.
T-cell epitopes on the 2C protein were widely distrib-
uted and their locations defined by the HLA-DR geno-
types of the T-cell donors. HLA-DR-identical subjects
recognized highly similar epitopes. HLA-DR4 associated
FIG. 4. Responses of coxsackievirus B4 (CBV4)-specific T-cell line to
BV4 2C protein, two GAD65 preparations, and peptides from the
C–GAD65 homology region. CBV4, coxsackievirus B4; med, culture
edium without the antigens; CBV4 p4 peptide, WLKVKILPEVKEKHE-
LSRL; CBV3 p4 peptide, WLKVKILPEVREKHEFLSRL; truncated CBV4
4 peptide, KILPEVKEKHEF; GAD65 peptide 1, IARFKMFPEVKEKG-
AALPR; GAD65 peptide 2, KMFPEVKEKGMAALPRLIAF; GAD65 pep-
ide 3, NMYAMMIARFKMFPEVKEKG.mainly with responsiveness to peptide p17 and a few
other peptides, whereas T-cell lines from HLA-DR1,3-
(
scarrying subjects responded to several peptides.
Whether the few differences in epitope recognition found
between the HLA-DR-identical subjects are explained by
differences in infection history, HLA-DR subtypes, or dif-
ferences in antigen processing demands further analy-
ses.
The sequence homology between the 2C protein and
the human GAD65 is of special interest as it has been
hypothesized that molecular mimicry may be the reason
for the destruction of pancreatic b-cells during develop-
ment of type 1 diabetes (Kaufman et al., 1992). Analysis of
his potential cross-reactivity was one of our main goals
n this study. The use of CBV4-specific T-cell lines en-
ures that the epitopes found by the synthetic peptides
re naturally processed epitopes of the CBV4. Re-
ponses obtained using these T-cell lines are thus more
pecific than those obtained by stimulating PBMC di-
ectly by synthetic CBV4 peptides, as the wide cross-
eactivity in T-cell recognition may result in nonspecific
esponsiveness induced by unrelated antigens (Wucher-
fennig and Strominger, 1995).
This study shows that peptide p4 containing the 2C–
AD65 homology region is indeed a T-cell epitope. In our
tudy peptide p4 stimulated six T-cell lines but only two
f them had been established from patients with type 1
iabetes. Furthermore, only two of eight T-cell lines es-
ablished from diabetic subjects recognized peptide p4,
ndicating that this recognition is not specific to type 1
iabetes. Restriction studies also indicated that p4 pep-
ide was recognized in the context of the neutral HLA-
R1 allele, and the diabetes risk alleles HLA-DR3 and
DR4 were thus not associated with responses to the
pitope. Moreover, T-cell lines which recognized this
pitope in 2C protein did not cross-react with GAD65. It
as to be also noted that the previous studies with
AD65-specific T-cell lines and synthetic GAD65 simi-
arly found no T-cell responses to the peptide containing
he 2C-GAD65 homology sequence (Bach et al., 1998;
ndl et al., 1997).
The few earlier studies which reported T-cell reactivity
o the homology region were conducted using PBMC
ultures, preventing evaluation of the cross-reactivity be-
ween the 2C protein and GAD65 (Atkinson et al., 1994;
chloot et al., 1997). Two 20-aa-long GAD65 peptides (aa
47–279), which contained the homology region within
heir overlapping 10-aa residues, have been reported to
e recognized by PBMC from subjects with type 1 dia-
etes (4 of 16) and by subjects with an increased risk for
ype 1 diabetes (7 of 15), but not by PBMC from healthy
ontrol subjects (none of 13) (Atkinson et al., 1994). That
tudy also showed that PBMC from the 3 individuals
esponding to one of the two GAD65 peptides containing
he homology sequence (aa 247–279) also responded to
CBV4 2C peptide containing the homology sequence
aa 32–47). In another study PBMC from healthy control
ubjects also responded to this homology peptide
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138 MARTTILA ET AL.(Schloot et al., 1997). Unfortunately these studies con-
tained only limited information of the complete HLA-DR
genotypes of the diabetic patients and no information on
the HLA genotypes of the healthy control subjects were
given. It may well be that the described responses were
associated with the HLA-DR alleles, which are not
equally distributed among patients with type 1 diabetes
and controls (She, 1996).
In our study the HLA restriction of the responses to the
homology region in the CBV4-specific T-cell lines was
studied using APC sharing either HLA-DR3 or HLA-DR1
with the T-cell donors. HLA-DR1 was needed for presen-
tation of the p4 peptide WLKVKILPEVKEKHEFLSRL,
whereas DR3 was unable to present this peptide to our
T-cell lines. Vreugdenhil and co-workers (1998) analyzed
HLA-DR binding affinities of peptides containing the PE-
VKEK region and reported that 20-aa-long GAD65 and 2C
peptides bound to HLA-DR1, -DR3, and -DR4 molecules.
In their study the 12-aa-long 2C peptide VKILPEVKEKHE
did not bind to the HLA-DR1 molecule, but it lacks the
carboxyterminal phenylalanine of the peptide KILPE-
VKEKHEF, used in our study. We also studied a T-cell line
from a healthy HLA-DR3, 6-positive subject who consis-
tently though weakly responded to peptide p4. Unfortu-
nately we lost this line before we had performed any
restriction studies.
In conclusion, we showed that CBV4 2C protein is
strongly immunogenic and its GAD65 homology region is
a T-cell epitope. However, the p4 peptide was recog-
nized as frequently by T-cell lines from patients with type
1 diabetes and healthy controls. The recognition showed
no association with the HLA risk alleles. Although our
data do not support the hypothesis that molecular mim-
icry between CBV4 2C protein and GAD65 autoantigen is
important in the pathogenesis of type 1 diabetes, further
studies are warranted. The T-cell cross-reactivities found
suggest that absolute sequence homology is not needed
for mimicry and also other enterovirus epitopes should
be studied for cross-reactivity. Our data apply only to
HLA-DR restricted helper T-cells isolated from peripheral
blood. T-cells isolated from other body compartments
and restricted by HLA-DQ or other HLA molecules as
well as class I-restricted cytotoxic T-cells may also be
important mediators in the process that finally may lead
to destruction of the pancreatic b-cells.
MATERIALS AND METHODS
CBV4 lysate antigen
Coxsackievirus B4 (ATCC) was grown in LLC cells.
Infected cell cultures were harvested when cells de-
tached freely from the flask surface. The infected cells
and supernatant fluid were frozen and quickly thawed
three times. This lysate antigen was inactivated with
b-propiolactone. Its protein concentration was measured
g
tusing the Pierce BCA protein assay reagent (Pierce,
Rockford, IL). It was used at a final concentration of 10
mg/ml.
GAD65
Spodoptera frugiperda (Sf9; ATCC) cells infected by
the baculovirus vector pk503-9 (kindly donated by K.
Keina¨nen, VTT, Espoo, Finland) carrying the human
GAD65 gene (Moody et al., 1995) were grown in our
laboratory (preparation 1). At appropriate cell density and
48–54 h after infection of the insect cells the cells were
washed once with PBS, and pellets were stored at
270°C. For GAD65 protein purification the cell pellets
were lysed by sonication and insoluble material was
removed by centrifugation (12,000 rpm for 10 min at 4°C).
For immunoaffinity purification GAD6 monoclonal anti-
body (Developmental Studies Hybridoma Bank, Iowa)
was used after coupling of the purified antibody (5 mg/ml
gel) to CNBr-activated Sepharose 4B (Pharmacia, Upp-
sala, Sweden). Supernatants from the infected cell ly-
sates and the antibody–resin mixture were then com-
bined and the antibody–antigen reaction was allowed to
proceed at pH 9.2 by rotating the mixture at 4°C. The
resin was batch-washed twice with 200 mM sodium
bicarbonate, pH 9.0, and transferred into a column which
was then eluted with 100 mM glycine–HCl, pH 2.7. The
effluent was neutralized and the precipitated GAD65 was
pelleted and solubilized in 100 mM NaHCO3, pH 9.2. The
urity of the preparations was confirmed using 7.5%
DS–PAGE and staining with Coomassie brilliant blue.
estern blot analysis was then performed using GAD6
r polyclonal rabbit anti-GAD65 as the primary antibody
nd horseradish peroxidase conjugate as the secondary
ntibody in an enhanced chemiluminescence assay
Amersham, Buckinghamshire, England). Only a 65-kDa
and was visible in Coomassie staining, indicating over
5% purity.
In addition another GAD65 preparation produced us-
ng baculovirus vector was purchased from DIAMYD
edical (Stockholm, Sweden) (preparation 2). The addi-
ives were removed by buffer exchange on a Sephadex
-25 column (NAP-5; Pharmacia Biotech) before use in
-cell cultures.
ST-2C protein
CBV4 2C protein was prepared as described
Ha¨rko¨nen et al., 1997). Full-size CBV4 cDNA was used
s a template to amplify the genes by polymerase chain
eaction. The genes were cloned into expression vector
GEX-2T and expressed as a fusion protein with GST
GST-2C) in Escherichia coli. GST-2C was purified on a
lutathione–Sepharose column (GST Gene Fusion Sys-
em; Pharmacia Biotech).
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139RESPONSES OF CBV4-SPECIFIC T-CELL LINES TO 2C PROTEINPeptides
Thirty-three 20-aa-long synthetic peptides with 10-aa
overlaps covered the whole CBV4 2C sequence of the
JBV strain and were synthesized (Jenkins et al., 1987)
Table 3). An additional truncated CBV4 2C peptide,
ILPEVKEKHEF; CBV3 2C peptide, WLKVKILPEVREKHE-
LNRL; and GAD65 peptides, IARFKMFPEVKEKG-
AALPR, KMFPEVKEKGMAALPRLIAF, and NMYAMMI-
RFKMFPEVKEKG from the region containing the homol-
gy region were synthesized. The peptides were
ynthesized by F-moc [N-(9-fluorenyl)methoxycarbonyl]
hemistry on a simultaneous multiple peptide synthe-
izer (SMPS 350; Zinsser Analytic, Frankfurt, Germany).
urity of the peptides was analyzed by reversed-phase
PLC (Hewlett–Packard 1100 series, Waldbronn, Ger-
TABLE 3
Thirty-Three 20-aa-Long Synthetic Peptides with 10-aa Overlaps
over the Whole Coxsackievirus B4 Nonstructural 2C Protein Se-
uence of JBV Strain (Jenkins et al., 1987)
Peptide Numbers of aa Sequence of aa
p1 aa 1–20 NNGWLKKFTEMTNACKGMEW
p2 aa 11–30 MTNACKGMEWIAVKIQKFIE
p3 aa 21–40 IAVKIQKFIEWLKVKILPEV
p4 aa 31–50 WLKVKILPEVKEKHEFLSRL
p5 aa 41–60 KEKHEFLSRLKQLPLLESQI
p6 aa 51–70 KQLPLLESQIATIEQSAPSQ
p7 aa 61–80 ATIEQSAPSQSDQEQLFSNV
p8 aa 71–90 SDQEQLFSNVQYFAHYCRKY
p9 aa 81–100 QYFAHYCRKYAPLYAAEAKR
p10 aa 91–110 APLYAAEAKRVFSLEKKMSN
p11 aa 101–120 VFSLEKKMSNYIQFKSKCRI
p12 aa 111–130 YIQFKSKCRIEPVCLLLHGS
p13 aa 121–140 EPVCLLLHGSPGAGKSVATN
p14 aa 131–150 PGAGKSVATNLIGRSLAEKL
p15 aa 141–160 LIGRSLAEKLNSSVYSLPPD
p16 aa 151–170 NSSVYSLPPDPDHFDGYKQQ
p17 aa 161–180 PDHFDGYKQQAVVIMDDLCQ
p18 aa 171–190 AVVIMDDLCQNPDGKDVSLF
p19 aa 181–200 NPDGKDVSLFCQMVSSVDFV
p20 aa 191–210 CQMVSSVDFVPPMAALEEKG
p21 aa 201–220 PPMAALEEKGILFTSPFVLA
p22 aa 211–230 ILFTSPFVLASTNAGSINAP
p23 aa 221–240 STNAGSINAPTVSDSRALAR
p24 aa 231–250 TVSDSRALARRFHFDMNIEV
p25 aa 241–260 RFHFDMNIEVISMYSQNGKI
p26 aa 251–270 ISMYSQNGKINMPMSVKTCD
p27 aa 261–280 NMPMSVKTCDEECCPVNFKR
p28 aa 271–290 EECCPVNFKRCCPLVCGKAI
p29 aa 281–300 CCPLVCGKAIQFIDRKTQVR
p30 aa 291–310 QFIDRKTQVRYSLDMLVTEM
p31 aa 301–320 YSLDMLVTEMFREYNHRHSV
p32 aa 311–330 FREYNHRHSVGATLEALFQG
p33 aa 321–340 GATLEALFQGPPVYREIKISany). Peptides were used at final concentration of 10–
00 mg/ml.
(
cuman subjects
Thirteen healthy laboratory staff members and 9 chil-
ren with type 1 diabetes volunteered to donate blood for
he study. The Joint Ethics Committee of the Turku Uni-
ersity and Turku University Hospital had approved this
tudy. Informed consent was obtained from all parents/
uardians.
-cell lines
Peripheral blood mononuclear cells were isolated
rom heparinized venous blood by Ficoll–Paque gradient
entrifugation. PBMC (2 3 106/ml) were incubated with
he CBV4 antigen (10 mg/ml) in RPMI 1640 medium sup-
lemented with 10% human AB serum, gentamycin sul-
ate (10 mg/ml), HEPES buffer solution, 1 M (20 ml/ml),
nd 3% glutamine (10 ml/ml). After 7 days, fresh medium
upplemented with IL-2 (20 U/ml) was added every sec-
nd or third day. After a total of 14 days from the begin-
ing, the T cells were restimulated with both CBV4 anti-
en and irradiated (30 Gy) autologous antigen-present-
ng cells (2 3 106 PBMC/ml). T-cell lines were
estimulated at 7-day intervals, IL-2 was added 2 days
fter antigen stimulation and at 2- to 3-day intervals
hereafter. All T-cell lines had more than two cycles of
timulation with CBV4 antigen, irradiated autologous
PC, and IL-2. The T-cell lines did not respond to control
ell lysate or to GST protein. Most T cells were CD4
ositive (average was 64.6%) when the phenotype of six
-cell lines was analyzed by flow cytometry (FACScan;
ecton–Dickinson, Mountain View, CA) using FITC- or
hycoerythrin-conjugated mAb (Coulter, Hialeah, FL) for
he CD4 and CD8 T-cell surface markers, respectively.
ymphocyte proliferation assay
Triplicate cultures of 5–10 3 103 T-cells per well were
ncubated with 2 3 104 antigen-presenting cells (PBMC)
nd antigen in 200-ml volumes in 96-well round-bottomed
microtiter plates for 2 days. Tritiated thymidine (2 mCi/ml)
was added 18 h before harvesting the cultures. Incorpo-
rated radioactivity was measured by a 1450 Microbeta
Plus liquid scintillation counter (Wallac, Turku, Finland).
Stimulation index was calculated by dividing the median
of stimulated triplicate culture wells by the median of the
control wells.
Antigen-specific IFN-g production
Supernatants from the microtiter plate well cultures of
peptide-stimulated T-cell lines were collected after 24 h
of culture. The presence of IFN-g protein in culture su-
ernatants was measured using a capture EIA. Ninety-
ix-well Maxisorb plates (Nunc, Roskilde, Denmark)
ere coated with monoclonal anti-human IFN-g antibodyCode M-700A; Endogen, Cambridge, MA) at 0.5 mg/well
oncentration. The plates were incubated for 2 h at 37°C
PH
c
s
c
b
B
140 MARTTILA ET AL.and then at 4°C overnight. After washes with PBS, plates
were blocked with 1% bovine serum albumin in PBS at
37°C for 30 min. Dilutions of recombinant human IFN-g
(19751N; Pharmingen, San Diego, CA) were used to cre-
ate a standard curve. Supernatant samples (200 ml/well)
and standards were then incubated in the wells at 37°C
for 2 h. After a wash with PBS–0.05% Tween, biotinylated
anti-human IFN-g monoclonal antibody (M-701; Endo-
gen) was added at 0.5 mg/ml (50 ml/well) concentration
and incubated at 37°C for 2 h. After a wash with PBS–
Tween, streptavidin–alkaline phosphatase complex
(Zymed, San Francisco, CA) was added and p-nitrophe-
nyl phosphate was used to develop the color, read at
405 nm.
HLA-DR restriction studies
To define the restriction element of each CBV4-spe-
cific T-cell line, cells were incubated with antigen and
antigen-presenting cells, which were selected to share
different DR alleles with the T-cell line donor. Cells with-
out any common DR alleles and autologous cells served
as negative and positive controls, respectively.
HLA-blocking experiments
Irradiated (30 Gy), autologous PBMCs were first incu-
bated with various antibodies [monoclonal antibodies
recognizing DR- (clone L243), DQ- (clone SPVL3), or
ABC- (clone w6/32) molecules] in final concentrations of
5 and 50 mg/ml at 37°C for 1 h. After incubation, the
BMCs were used as antigen-presenting cells.
LA typing
HLA typing of blood donors was done using panels of
ommercial antisera (Biotest, Dreieich, Germany) in a
tandard microlymphocytotoxicity test. B-cells for HLA
lass II typing were enriched using immunomagnetic
eads (Dynal, Oslo, Norway).
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